G-5903 GW2580, Free Base, >99%

  • Size
  • US $
  • €
  • £
  • ¥
  • 100 mg
  • 86
  • 79
  • 71
  • 11,300
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 207
  • 191
  • 171
  • 27,200
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 446
  • 412
  • 370
  • 58,500
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 1,725
  • 1,593
  • 1,431
  • 226,300
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 2,670
  • 2,467
  • 2,216
  • 350,300
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
Compare Quality and Prices — LC Labs vs. Other Suppliers
  • M.W. 366.41
  • C20H22N4O3
  • [870483-87-7]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 40 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 200 different labs have purchased GW2580 from LC Labs since its introduction in 2010 (either directly from us or from our many distributors, many of whom resell under their own labels).
  • GW2580 is a small-molecule inhibitor of cFMS kinase; at 60 nM it inhibited human cFMS kinase completely in vitro and was inactive against 26 other kinases. GW2580 inhibited lipopolysaccharide (LPS)-induced TNF production in mice, but not LPS-induced TNF production in freshly isolated human monocytes and mouse macrophages in vitro. Also, GW2580 at 1 µM totally inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes, and prevented bone degradation in cultures of rat calvaria and rat fetal long bone in vitro. Conway, J.G., et al. "Inhibition of colony-stimulating-factor-1 signaling in vitro with the orally bioavailable cFMS kinase inhibitor GW2580." Proc. Natl. Acad. Sci. USA 102: 16078-16083 (2005).
  • In an arthritic rat model, GW2580 inhibited joint connective tissue and bone destruction, and thus preserved joint integrity. Conway, J.G., et al. "Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats." J. Pharmacol. Exp. Ther. 326: 41-50 (2008).
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
140